Annals of the Rheumatic Diseases

OP0154 COMORBIDITY CLUSTERS IN ANKYLOSING SPONDYLITIS AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPAIRMENT: DATA FROM THE PSOAS COHORT.

Annals of the Rheumatic Diseases

P. Karmacharya, C. S. Crowson, D. Poudel, J. M. Davis, A. Ogdie, J. Liew, M. Ward, M. Ishimori, M. Weisman, M. Brown, M. Rahbar, M. Hwang, J. D. Reveille, L. S. Gensler

OP0023 A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG.

Annals of the Rheumatic Diseases

A. Deodhar, A. Kivitz, M. Magrey, J. A. Walsh, P. J. Mease, M. Greenwald, R. Calheiros, F. Kianifard, C. Elam, K. Nagar, A. Winseck, L. S. Gensler

OP0019 BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 24-WEEK EFFICACY & SAFETY FROM BE MOBILE 2, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED STUDY.

Annals of the Rheumatic Diseases

D. Van der Heijde, X. Baraliakos, M. Dougados, M. Brown, D. Poddubnyy, F. Van den Bosch, N. Haroon, H. Xu, T. Tomita, L. S. Gensler, M. Oortgiesen, C. Fleurinck, T. Vaux, A. Marten, A. Deodhar

OP0017 RECAPTURE RATES WITH IXEKIZUMAB AFTER WITHDRAWAL OF THERAPY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS AT WEEK 104 FROM A RANDOMIZED PLACEBO-CONTROLLED WITHDRAWAL STUDY.

Annals of the Rheumatic Diseases

R. B. M. Landewé, D. Poddubnyy, P. Rahman, R. Bolce, S. Liu Leage, J. Lisse, A. Leung, S. Y. Park, L. S. Gensler

POS0459 UNSUPERVISED CLUSTERING IDENTIFIES UNIQUE SUBSETS OF PATIENTS IN A RACIALLY AND ETHNICALLY DIVERSE RHEUMATOID ARTHRITIS COHORT.

Annals of the Rheumatic Diseases

G. Lui, E. Noss, N. Singh, J. Andrews, J. Graf, K. Wysham

POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE.

Annals of the Rheumatic Diseases

M. Yang, P. Katz, D. Paez, A. Carvidi, M. Matloubian, M. Nakamura, L. S. Gensler

POS0923 INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1.

Annals of the Rheumatic Diseases

F. Van den Bosch, D. Poddubnyy, J. Stigler, A. Ostor, S. D’angelo, V. Navarro-Compán, I. H. Song, T. Gao, F. Ganz, L. S. Gensler

POS0904 FACTORS ASSOCIATED WITH SWITCHING FROM ONE ANTI-TNF AGENT TO ANOTHER ANTI-TNF, OR IL17 AGENT IN PATIENT WITH ANKYLOSING SPONDYLITIS.

Annals of the Rheumatic Diseases

M. Hwang, M. Weisman, L. S. Gensler, A. Tahanan, M. Ishimori, T. Hunter, R. Bolce, J. Lisse, M. Rahbar, M. Shan, J. D. Reveille

POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY.

Annals of the Rheumatic Diseases

D. Van der Heijde, A. Deodhar, L. S. Gensler, D. Poddubnyy, A. Kivitz, M. Dougados, N. De Peyrecave, M. Oortgiesen, T. Vaux, C. Fleurinck, X. Baraliakos

Pages